logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Problem drug use (PDU)

displaying all

Category Title
GPS GPS-0. Nationwide surveys among the general population: Bibliographic references
GPS GPS-1. Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000 Part (i) Survey methods
GPS GPS-1. Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000 Part (ii) All adults (aged 15–64)
GPS GPS-1. Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000 Part (iii) Young adults (aged 15–34)
GPS GPS-1. Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000 Part (iv) Youth (15–24)
GPS GPS-2. Last 12 months prevalence of drug use by age and country, most recent national general population survey available since 2000 Part (i) All adults (aged 15–64)
GPS GPS-2. Last 12 months prevalence of drug use by age and country, most recent national general population survey available since 2000 Part (ii) Young adults (15–34)
GPS GPS-2. Last 12 months prevalence of drug use by age and country, most recent national general population survey available since 2000 Part (iii) Youth (aged 15–24)
GPS GPS-3. Last 30 days prevalence of drug use by age and country, most recent national general population survey available since 2000 Part (i) All adults (aged 15–64)
GPS GPS-3. Last 30 days prevalence of drug use by age and country, most recent national general population survey available since 2000 Part (ii) Young adults (15–34)
GPS GPS-3. Last 30 days prevalence of drug use by age and country, most recent national general population survey available since 2000 Part (iii) Youth (aged 15–24)
GPS GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (i) All adults male (aged 15–64)
GPS GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (ii) All adults female (aged 15–64)
GPS GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (iii) Young adults male (aged 15–34)
GPS GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (iv) Young adults female (aged 15–34)
GPS GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (v) Youth male (aged 15–24)
GPS GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (vi) Youth female (aged 15–24)
GPS GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (i) All adults male (aged 15–64)
GPS GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (ii) All adults female (aged 15–64)
GPS GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (iii) Young adults male (aged 15–34)
GPS GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (iv) Young adults female (aged 15–34)
GPS GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (v) Youth male (aged 15–24)
GPS GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (vi) Youth female (aged 15–24)
GPS GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (i) All adults male (aged 15–64)
GPS GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (ii) All adults female (aged 15–64)
GPS GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (iii) Young adults male (aged 15–34)
GPS GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (iv) Young adults female (aged 15–34)
GPS GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (v) Youth male (aged 15–24)
GPS GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (vi) Youth female (aged 15–24)
GPS GPS-7. Lifetime prevalence of drug use in all available national general population surveys Part (i) Survey methods
GPS GPS-7. Lifetime prevalence of drug use in all available national general population surveys Part (ii) All adults (aged 15–64)
GPS GPS-7. Lifetime prevalence of drug use in all available national general population surveys Part (iii) Young adults (aged 15–34)
GPS GPS-7. Lifetime prevalence of drug use in all available national general population surveys Part (iv) Youth (aged 15–24)
GPS GPS-8. Last 12 months prevalence of drug use in all available national general population surveys Part (i) All adults (aged 15–64)
GPS GPS-8. Last 12 months prevalence of drug use in all available national general population surveys Part (ii) Young adults (15–34)
GPS GPS-8. Last 12 months prevalence of drug use in all available national general population surveys Part (iii) Youth (aged 15–24)
GPS GPS-9. Last 30 days prevalence of drug use in all available national general population surveys Part (i) All adults (aged 15–64)
GPS GPS-9. Last 30 days prevalence of drug use in all available national general population surveys Part (ii) Young adults (15–34)
GPS GPS-9. Last 30 days prevalence of drug use in all available national general population surveys Part (iii) Youth (aged 15–24)
GPS GPS-10. Frequency of use of cannabis amongst users in the last 30 days in national general population surveys Part (ii) All adults (aged 15–64) - 2007 field trial
GPS GPS-10. Frequency of use of cannabis amongst users in the last 30 days in national general population surveys Part (iii) All adults (aged 15–64) - 2004 field trial
GPS GPS-121. Methodological information for nation-wide surveys among the general population
GPS GPS-1. Last 12 months prevalence of cannabis use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for youth (aged 15 to 24)
GPS GPS-2. Continuation rates of cannabis use (last 12 months use and last 30 days use as proportions of lifetime use)
GPS GPS-4. Trends in last 12 months prevalence of cannabis use among young adults (aged 15 to 34) Part (i) All countries
GPS GPS-4. Trends in last 12 months prevalence of cannabis use among young adults (aged 15 to 34) Part (ii) Countries with three or more surveys
GPS GPS-5. Last 12 months prevalence of amphetamines use among young adults (aged 15–34) and youth (aged 15–24)
GPS GPS-6. Last 12 months prevalence of amphetamines use among all adults (aged 15–64), young adults (aged 15–34) and youth (aged 15–24)
GPS GPS-7. Last 30 days prevalence of cannabis use among all adults (aged 15–64), young adults (aged 15–34) and youth (aged 15–24)
GPS GPS-8. Trends in last 12 months use of amphetamines among young adults (aged 15 to 34) Part (i) All countries
GPS GPS-8. Trends in last 12 months use of amphetamines among young adults (aged 15 to 34) Part (ii) Countries with three or more surveys
GPS GPS-9. Last 12 months prevalence of ecstasy use among all adults (aged 15–64), young adults (aged 15–34) and youth (aged 15–24) Part (i) All age groups
GPS GPS-10. Last 12 months prevalence of cannabis use by age group in United Kingdom (E&W)
GPS GPS-11. Continuation rates of ecstasy use (last 12 months use and last 30 days use as proportions of lifetime use)
GPS GPS-12. Last 12 months prevalence of cannabis use by age group Part (i) Selected EU-15 Member States
GPS GPS-12. Last 12 months prevalence of cannabis use by age group Part (ii) Selected ‘new’ EU Member States
GPS GPS-13. Last 12 months prevalence of cocaine use among all young adults (aged 15 to 34) by gender
GPS GPS-14. Trends in last 12 months prevalence of cocaine use among young adults (aged 15 to 34) Part (i) All countries
GPS GPS-14. Trends in last 12 months prevalence of cocaine use among young adults (aged 15 to 34) Part (ii) Countries with three or more surveys
GPS GPS-15. Last 12 months prevalence of cocaine use among all adults (aged 15–64), young adults (aged 15–34) and youth (aged 15–24)
GPS GPS-16. Continuation rates of cocaine use (last 12 months use and last 30 days use as proportions of lifetime use)
GPS GPS-17. Last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 to 34)
GPS GPS-18. Overview of drug prevalence estimates in Europe for all adults (aged 15–64) and young adults (aged 15–34) Part (i) Cannabis use — lifetime experience, last 12 months and last 30 days prevalence
GPS GPS-18. Overview of drug prevalence estimates in Europe for all adults (aged 15–64) and young adults (aged 15–34) Part (ii) Cocaine, amphetamines and ecstasy use — lifetime experience, last 12 months and last 30 days prevalence
GPS GPS-20. Lifetime and last 12 months prevalence of cocaine use among young adults (aged 15–34) in Europe, Canada, Australia and the USA
GPS GPS-21. Trends in last 12 months prevalence of ecstasy use among young adults (aged 15–34) Part (i) All countries
GPS GPS-21. Trends in last 12 months prevalence of ecstasy use among young adults (aged 15–34) Part (ii) Countries with three or more surveys
GPS GPS-22. Continuation rates of amphetamine use (last 12 months use and last 30 days use as proportions of lifetime use)
GPS GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15–34) Part (i) United Kingdom (E&W)
GPS GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15–34) Part (ii) Denmark
GPS GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15–34) Part (iii) Germany
GPS GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15–34) Part (iv) Spain
GPS GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15–34) Part (v) France
PDU PDU-1. Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15 to 64), studies from 2004 to 2009 - last study available Part (i) Estimates of overall problem drug use
PDU PDU-1. Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15 to 64), 2004 to 2009 — last study available Part (ii) Estimates of problem opioid use
PDU PDU-2. Estimates of the prevalence of injecting drug use (rate per 1000 population aged 15 to 64), 2004 to 2009 — last study available
PDU PDU-0. Estimates of prevalence of problem drug use at national and subnational level: bibliographic references
PDU PDU-1. Estimates of prevalence of problem drug use at national level: Summary Table, 2004–2009, rate per 1000 aged 15–64 Part (i) Overall problem drug use
PDU PDU-1. Estimates of prevalence of problem drug use at national level: Summary Table, 2004-2009, rate per 1000 aged 15–64 Part (ii) Injecting drug use
PDU PDU-1. Estimates of prevalence of problem drug use at national level: Summary Table, 2004-2009, rate per 1000 aged 15-64 Part (iii) Problem opioid use
PDU PDU-6. Estimated trends in the prevalence of problem and injecting drug use - 2004 to 2009 (rate per 1 000 population aged 15 to 64): Combined estimates per country Part (i) Estimated trends of overall problem drug use
PDU PDU-6. Estimated trends in the prevalence of problem and injecting drug use — 2004 to 2009 (rate per 1 000 population aged 15 to 64): Combined estimates per country Part (ii) Estimated trends of problem opioid use
PDU PDU-6. Estimated trends in the prevalence of problem and injecting drug use — 2004 to 2009 (rate per 1000 population aged 15 to 64): Combined estimates per country Part (iii) Estimated trends of injecting drug use
PDU PDU-6. Estimated trends in the prevalence of problem and injecting drug use — 2004 to 2009 (rate per 1000 population aged 15 to 64): Combined estimates per country Part (iv) Estimated trends of problem stimulant use
PDU PDU-102. Prevalence of problem drug use at national level - full listing of studies Part (i) Problem drug use
PDU PDU-102. Prevalence of problem drug use at national level - full listing of studies Part (ii) Injecting drug use
PDU PDU-103. Prevalence of problem drug use at subnational level - full list of studies Part (i) Problem drug users
PDU PDU-103. Prevalence of problem drug use at subnational level — full list of studies Part (ii) Injecting drug users
PDU PDU-104. Trends in injecting drug use — percentage currently injecting among all clients entering treatment for primary drug heroin, 2004 to 2009
TDI TDI-1. Trend in estimated number of new clients entering treatment by primary drug used, from 2004 to 2009 Part (i) Percentage distribution by primary drug
TDI TDI-1. Trend in estimated number of new clients entering treatment by primary drug used, from 2004 to 2009 Part (ii) Numbers of clients by primary drug
TDI TDI-2. New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants, other drugs in 2009. Part (i) New clients
TDI TDI-2. New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants, other drugs in 2009 in all EU Member States Part (ii) All clients
TDI TDI-3. Trend in estimated number of all clients entering treatment by primary drug used, from 2004 to 2009 Part (i) Percentage distribution by primary drug
TDI TDI-3. Trend in estimated number of all clients entering treatment by primary drug used, from 2004 to 2009 Part (ii) Numbers of clients by primary drug
TDI TDI-7. New outpatient clients injecting opioid as primary drug from 2004 to 2009 in 15 countries supplying data
TDI TDI-0. Data sources for clients entering treatment
TDI TDI-1. Clients entering treatment and treatment units by country, 2009 or most recent year available
TDI TDI-2. Clients entering treatment and reporting treatment units, 1998 to 2009 Part (i) New clients by country and year of treatment
TDI TDI-2. Clients entering treatment and reporting treatment units, 1998 to 2009 Part (ii) All clients by country and year of treatment
TDI TDI-2. Clients entering treatment and reporting treatment units, 1998 to 2009 Part (iii) Reporting treatment units by country and year of treatment
TDI TDI-2. Clients entering treatment and reporting treatment units, 1998 to 2009 Part (iv) Types of reporting treatment unit by country
TDI TDI-3. New clients entering treatment by primary drug, 1998 to 2009 Part (i) New heroin clients by country and year of treatment (%)
TDI TDI-3. New clients entering treatment by primary drug, 1998 to 2009 Part (ii) New cocaine clients by country and year of treatment (%)
TDI TDI-3. New clients entering treatment by primary drug, 1998 to 2009 Part (iii) New stimulants (amphetamines and MDMA) clients by country and year of treatment (%)
TDI TDI-3. New clients entering treatment by primary drug, 1998 to 2009 Part (iv) New cannabis clients by country and year of treatment (%)
TDI TDI-4. Demographic characteristics of clients entering treatment, 2009 or most recent year available Part (i) New clients by country and gender (%)
TDI TDI-4. Demographic characteristics of clients entering treatment, 2009 or most recent year available Part (ii) All clients by country and gender (%)
TDI TDI-4. Demographic characteristics of clients entering treatment, 2009 or most recent year available Part (iii) New clients by country and age (%)
TDI TDI-4. Demographic characteristics of clients entering treatment, 2009 or most recent year available Part (iv) All clients by country and age (%)
TDI TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2009 or most recent year available Part (i) New clients by country and primary drug (%), regardless whether they inject the drug
TDI TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2009 or most recent year available Part (ii) All clients by country and primary drug (%), regardless whether they inject the drug
TDI TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2009 or most recent year available Part (iii) New clients by country and rates of injection of primary drug (%)
TDI TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2009 or most recent year available Part (iv) All clients by country and rates of injection of primary drug (%)
TDI TDI-6. Incidence of treatment demand for drug use, 2009 or most recent year available. New clients by country (rate per 100 000 population aged 15 to 64 years old)
TDI TDI-7. Data coverage, 2009 or most recent year available Part (i) Clients entering treatment by country and type of treatment centre and type of client
TDI TDI-7. Data coverage, 2009 or most recent year available Part (ii) Units by country and type of treatment centre and reporting status
TDI TDI-8. Primary use of stimulants of clients entering treatment, 2009 or most recent year available Part (i) New clients by country and type of stimulant (%)
TDI TDI-8. Primary use of stimulants of clients entering treatment, 2009 or most recent year available Part (ii) All clients by country and type of stimulant (%)
TDI TDI-9. Demographic characteristics of clients entering outpatient treatment, 2009 or most recent year available Part (i) New outpatient clients by country and gender
TDI TDI-9. Demographic characteristics of clients entering outpatient treatment, 2009 or most recent year available Part (ii) All outpatient clients by country and by gender
TDI TDI-9. Demographic characteristics of clients entering outpatient treatment, 2009 or most recent year available Part (iii) New outpatient clients by country and age
TDI TDI-9. Demographic characteristics of clients entering outpatient treatment, 2009 or most recent year available Part (iv) All outpatient clients by country and age
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (i) New outpatient clients, age distribution by primary drug (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (ii) New outpatient clients, primary drug distribution by age (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (iii) All outpatient clients, age distribution by primary drug (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (iv) All outpatient clients, primary drug distribution by age (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (v) New inpatient clients, age distribution by primary drug (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (vi) New inpatient clients, primary drug distribution by age (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (vii) All inpatient clients, age distribution by primary drug (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (viii) All inpatient clients, primary drug distribution by age (%)
TDI TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (i) New outpatient clients, age at first use distribution by primary drug (%)
TDI TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (ii) New outpatient clients, primary drug distribution by age at first use (%)
TDI TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (iii) All outpatient clients, age at first use distribution by primary drug (%)
TDI TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (iv) All outpatient clients, primary drug distribution by age at first use (%)
TDI TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (v) New inpatient clients, age at first use distribution by primary drug (%)
TDI TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (vi) New inpatient clients, primary drug distribution by age at first use (%)
TDI TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (vii) All inpatient clients, age at first use distribution by primary drug (%)
TDI TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (viii) All inpatient clients, primary drug distribution by age at first use (%)
TDI TDI-12. Education status of clients entering treatment, 2009 or most recent year available Part (i) New outpatient clients by country and education status (%)
TDI TDI-12. Education status of clients entering treatment, 2009 or most recent year available Part (ii) All outpatient clients by country and education status (%)
TDI TDI-12. Education status of clients entering treatment, 2009 or most recent year available Part (iii) New inpatient clients by country and education status (%)
TDI TDI-12. Education status of clients entering treatment, 2009 or most recent year available Part (iv) All inpatient clients by country and education status (%)
TDI TDI-13. Labour status of clients entering treatment, 2009 or most recent year available Part (i) New outpatient clients by country and labour status (%)
TDI TDI-13. Labour status of clients entering treatment, 2009 or most recent year available Part (ii) All outpatient clients by country and labour status (%)
TDI TDI-13. Labour status of clients entering treatment, 2009 or most recent year available Part (iii) New inpatient clients by country and labour status (%)
TDI TDI-13. Labour status of clients entering treatment, 2009 or most recent year available Part (iv) All inpatient clients by country and labour status (%)
TDI TDI-14. Persons with whom client is living on entering treatment, 2009 or most recent year available Part (i) New outpatient clients by country and with whom living (%)
TDI TDI-14. Persons with whom client is living on entering treatment, 2009 or most recent year available Part (ii) All outpatient clients by country and with whom living (%)
TDI TDI-14. Persons with whom client is living on entering treatment, 2009 or most recent year available Part (iii) New inpatient clients by country and with whom living (%)
TDI TDI-14. Persons with whom client is living on entering treatment, 2009 or most recent year available Part (iv) All inpatient clients by country and with whom living (%)
TDI TDI-15. Type of accommodation of clients entering treatment, 2009 or most recent year available Part (i) New clients entering outpatient treatment by country and type of accommodation (%)
TDI TDI-15. Type of accommodation of clients entering treatment, 2009 or most recent year available Part (ii) All clients entering outpatient treatment by country and type of accommodation (%)
TDI TDI-15. Type of accommodation of clients entering treatment, 2009 or most recent year available Part (iii) New clients entering inpatient treatment by country and type of accommodation (%)
TDI TDI-15. Type of accommodation of clients entering treatment, 2009 or most recent year available Part (iv) All clients entering inpatient treatment by country and type of accommodation (%)
TDI TDI-16. Source of referral of clients entering treatment, 2009 or most recent year available Part (i) New outpatient clients by country and source of referral (%)
TDI TDI-16. Source of referral of clients entering treatment, 2009 or most recent year available Part (ii) All outpatient clients by country and source of referral (%)
TDI TDI-16. Source of referral of clients entering treatment, 2009 or most recent year available Part (iii) New inpatient clients by country and source of referral (%)
TDI TDI-16. Source of referral of clients entering treatment, 2009 or most recent year available Part (iv) All inpatient clients by country and source of referral (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2009 or most recent year available Part (i) New opioid outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2009 or most recent year available Part (ii) All opioid outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2009 or most recent year available Part (iii) New cocaine (HCl and crack) outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2009 or most recent year available Part (iv) All cocaine (HCl and crack) outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2009 or most recent year available Part (v) New stimulants (other than cocaine) outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2009 or most recent year available Part (vi) All stimulants (other than cocaine) outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2009 or most recent year available Part (vii) New hypnotics and sedatives outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2009 or most recent year available Part (viii) All hypnotics and sedatives outpatient clients by country and usual route of administration
TDI TDI-18. Frequency of use of primary drug of clients entering treatment, 2009 or most recent year available Part (i) New outpatient clients by primary drug and frequency of use (%)
TDI TDI-18. Frequency of use of primary drug of clients entering treatment, 2009 or most recent year available Part (ii) All outpatient clients by primary drug and frequency of use (%)
TDI TDI-18. Frequency of use of primary drug of clients entering treatment, 2009 or most recent year available Part (iii) New inpatient clients by primary drug and frequency of use (%)
TDI TDI-18. Frequency of use of primary drug of clients entering treatment, 2009 or most recent year available Part (iv) All inpatient clients by primary drug and frequency of use (%)
TDI TDI-19. Primary drug of clients entering treatment, 2009 or most recent year available Part (i) New outpatient clients by country and primary drug (%)
TDI TDI-19. Primary drug of clients entering treatment, 2009 or most recent year available Part (ii) All outpatient clients by country and primary drug (%)
TDI TDI-19. Primary drug of clients entering treatment, 2009 or most recent year available Part (iii) New inpatient clients by country and primary drug (%)
TDI TDI-19. Primary drug of clients entering treatment, 2009 or most recent year available Part (iv) All inpatient clients by country and primary drug (%)
TDI TDI-21. Gender ratio by primary drug of clients entering treatment, 2009 or most recent year available Part (i) New outpatient clients, ratio of males to females by country and primary drug
TDI TDI-21. Gender ratio by primary drug of clients entering treatment, 2009 or most recent year available Part (ii) All outpatient clients, ratio of males to females by country and primary drug
TDI TDI-21. Gender ratio by primary drug of clients entering treatment, 2009 or most recent year available Part (iii) New inpatient clients, ratio of males to females by country and primary drug
TDI TDI-21. Gender ratio by primary drug of clients entering treatment, 2009 or most recent year available Part (iv) All inpatient clients, ratio of males to females by country and primary drug
TDI TDI-22. Secondary drugs cited by clients entering treatment, 2009 or most recent year available Part (i) Outpatient units
TDI TDI-22. Secondary drugs cited by clients entering treatment, 2009 or most recent year available Part (ii) Inpatient units
TDI TDI-24. Type of treatment centre by primary drug of clients entering treatment, 2009 or most recent year available Part (i) New clients by country and primary drug and type of treatment centre (%)
TDI TDI-24. Type of treatment centre by primary drug of clients entering treatment, 2009 or most recent year available Part (ii) All clients by country and primary drug and type of treatment centre (%)
TDI TDI-25. Age distribution of all clients entering outpatient treatment by primary drug and gender, 2009 or most recent year available
TDI TDI-32. Mean age of clients entering treatment by primary drug and gender, 2009 or most recent year available Part (i) Outpatient clients
TDI TDI-32. Mean age of clients entering treatment by primary drug and gender, 2009 or most recent year available Part (ii) Inpatient clients
TDI TDI-33. Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering treatment, 2009 or most recent year available Part (i) Outpatient units
TDI TDI-33. Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering treatment, 2009 or most recent year available Part (ii) Inpatient units
TDI TDI-36. Primary amphetamine use among new clients entering treatment (%), 2003 to 2009
TDI TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2009 or most recent year available Part (i) All clients by country and primary drug and type of treatment unit
TDI TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2009 or most recent year available Part (ii) Outpatient clients by primary drug and mean age, gender ratio
TDI TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2009 or most recent year available Part (iii) Inpatient clients by primary drug and mean age, gender ratio
TDI TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2009 or most recent year available Part (iv) Outpatient clients by secondary drug and primary drug
TDI TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2009 or most recent year available Part (v) Inpatient clients by secondary drug and primary drug
TDI TDI-38. Clients in treatment by primary drug, all types of treatment centre, 2007 or most recent year available Part (i) Number of clients by country, primary drug, and incidence/prevalence
TDI TDI-38. Clients in treatment by primary drug, all types of treatment centre, 2007 or most recent year available Part (ii) Percentage of clients with known primary drug, by country, primary drug and incidence/prevalence
TDI TDI-38. Table TDI-38: Clients in treatment by primary drug, all types of treatment centre, 2007 or most recent year available Part (iii) Percentage of clients injecting their primary drug by country, primary drug and incidence/prevalence
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (i) All opioid outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (ii) All cocaine (HCI and 'crack') outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (iii) All stimulants (other than cocaine) outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (iv) All hallucinogen outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (v) All hypnotics and sedatives outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (vi) All volatile inhalant outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (vii) All cannabis outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (viii) All 'other drugs' outpatient clients by country and by age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (i) New opioid inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (ii) New cocaine (HCI and 'crack') inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (iii) New stimulants (other than cocaine) inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (iv) New hallucinogen inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (v) New hypnotics and sedatives inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (vi) New volatile inhalant inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (vii) New cannabis inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (viii) New 'other drugs' inpatient clients by country and by age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (i) All opioid inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (ii) All cocaine (HCI and 'crack') inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (iii) All stimulants (other than cocaine) inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (iv) All hallucinogen inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (v) All hypnotics and sedatives inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (vi) All volatile inhalant inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (vii) All cannabis inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (viii) All 'other drugs' inpatient clients by country and by age
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (i) New opioid outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (ii) New cocaine (HCI and 'crack') outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (iii) New stimulants (other than cocaine) outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (iv) New hallucinogen outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (v) New hypnotics and sedatives outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (vi) New volatile inhalant outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (vii) New cannabis outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (viii) New 'other drugs' outpatient clients by country and by age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (i) All opioid outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (ii) All cocaine (HCI and 'crack') outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (iii) All stimulants (other than cocaine) outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (iv) All hallucinogen outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (v) All hypnotics and sedatives outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (vi) All volatile inhalant outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (vii) All cannabis outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (viii) All 'other drugs' outpatient clients by country and by age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (i) New opioid inpatient clients by country and age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (ii) New cocaine (HCI and 'crack') inpatient clients by country and age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (iii) New stimulants (other than cocaine) inpatient clients by country and age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (iv) Number of clients using hallucinogens as primary drug
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (v) New hypnotics and sedatives inpatient clients by country and age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (vi) New volatile inhalant inpatient clients by country and age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (vii) New cannabis inpatient clients by country and age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (viii) New 'other drugs' inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (i) All opioid inpatient clients by country and age at first
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (ii) All cocaine (HCI and 'crack') inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (iii) All stimulants (other than cocaine) inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (iv) All hallucinogen inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (v) All hypnotics and sedatives inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (vi) All volatile inhalant inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (vii) All cannabis inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (viii) All 'other drugs' inpatient clients by country and by age at first use
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2009 or most recent year available Part (i) New opioid outpatient clients by country and frequency of use (%)
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2009 or most recent year available Part (ii) All opioid outpatient clients by country and frequency of use (%)
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2009 or most recent year available Part (iii) New cocaine (HCI and ‘crack’) outpatient clients by country and frequency of use (%)
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2009 or most recent year available Part (iv) All cocaine (HCI and ‘crack’) outpatient clients by country and frequency of use (%)
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2009 or most recent year available Part (v) New stimulants (other than cocaine) outpatient clients by country and frequency of use (%)
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2009 or most recent year available Part (vi) All stimulants (other than cocaine) outpatient clients by country and frequency of use (%)
TDI TDI-111. All clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (vii) New cannabis outpatient clients by country and frequency of use (%)
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2009 or most recent year available Part (viii) All cannabis outpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2009 or most recent year available Part (i) New opioid inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2009 or most recent year available Part (ii) All opioid inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2009 or most recent year available Part (iii) New cannabis inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2009 or most recent year available Part (iv) All cannabis inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2009 or most recent year available Part (v) New stimulants (other than cocaine) inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2009 or most recent year available Part (vi) All stimulants (other than cocaine) inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2009 or most recent year available Part (vii) New cocaine (HCI and ‘crack’) inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2009 or most recent year available Part (viii) All cocaine (HCI and ‘crack’) inpatient clients by country and frequency of use (%)
TDI TDI-113. All clients entering treatment for opioids by country and type of opioid misused (%), 2007 or most recent year available
TDI TDI-114. Primary opioids distribution (percent) among all clients entering treatment by country and type of treatment centre (%), 2009
TDI TDI-115. HCL and crack use of clients entering outpatient treatment, 2009 or most recent year available Part (i) New outpatient clients by country and type of cocaine product
TDI TDI-115. HCL and crack use of clients entering outpatient treatment, 2009 or most recent year available Part (ii) All outpatient clients by country and type of cocaine product
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (i) New opioid outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (ii) New cocaine (HCI and 'crack') outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (iii) New stimulants (other than cocaine) outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (iv) New hallucinogen outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (v) New hypnotics and sedatives outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (vi) New volatile inhalant outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (vii) New cannabis outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (viii) New 'other drugs' outpatient clients by country and by age
DRD DRD-0. Drug-induced deaths recorded in EU Member States according to national definitions: sources and bibliographic references
DRD DRD-1. Summary of characteristics of the deceased in drug-induced deaths according to national definitions Part (i) Demographic characteristics, 2009 or last year with available information
DRD DRD-1. Summary of characteristics of the deceased in drug-induced deaths according to national definitions Part (ii) Numbers of drug-induced deaths and toxicology, 2009 or last year with available information
DRD DRD-1. Summary of characteristics of the deceased in drug-induced deaths according to national definitions Part (iii) Demographic characteristics and toxicology, 1990 or earliest year with available information
DRD DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (i) Total drug-induced deaths, 1995 to 2009
DRD DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (ii) Male drug-induced deaths, 1995 to 2009
DRD DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (iii) Female drug-induced deaths, 1995 to 2009
DRD DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (iv) Total drug-induced deaths under the age of 25 years, 1995 to 2009
DRD DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (v) Totals and indexes, 1995 to 2009
DRD DRD-3. Number of drug-induced deaths recorded in EU Member States and Norway according to EMCDDA standard definition 'Selection B', 1995 to 2009
DRD DRD-4. Number of drug-induced deaths recorded in EU Member States according to EMCDDA standard definition 'Selection D', 1995 to 2009
DRD DRD-5. Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males) Part (i) Population mortality rates, 2009 or last year with available information
DRD DRD-5. Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males) Part (ii) Proportional mortality due to drug-induced deaths, 2009 or last year with available information
DRD DRD-5. Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males) Part (iii) Estimated mortality (numbers and population rates) due to AIDS attributable to injection drug use
DRD DRD-106. Methodological features of drug-induced deaths reported by Reitox national focal points (Based on national definitions – Reitox Standard Table 5).
DRD DRD-107. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (i) Total drug-induced deaths, 1985 to 2009
DRD DRD-107. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (ii) Totals and indexes, 1985 to 2009
DRD DRD-108. Drug-induced deaths: Detailed qualitative national information on deaths due to specific substances in EU Member States (2010 National reports)
DRD DRD-1. Proportion of drug-induced deaths that show presence of opioids for the most recent year reported
DRD DRD-2. Proportion of drug-induced deaths occurring under the age of 25 years for the most recent year reported
DRD DRD-3. Trends in mean age of drug-induced deaths in some of the EU-15 Member States, 1990 to 2009
DRD DRD-4. Trends in mean age of drug-induced deaths in some new EU Member States, 1990 to 2009
DRD DRD-5. lndexed trends in drug-induced deaths and in the numbers of deaths occurring under the age of 25 Part (i) Indexed trend in the EU-15 Member States and Norway 1990-2008
DRD DRD-5. lndexed trends in drug-induced deaths and in the numbers of deaths occurring under the age of 25 Part (ii) Indexed trend in the new Member States, 1990-2008
DRD DRD-6. Indexed overall trends for males and females in drug-induced deaths in the EU-15 Member States and Norway, 1990 to 2008
DRD DRD-7. Mortality due to drug-induced deaths among all adults (15 to 64 years) in European countries for the most recent year reported Part (i) Mortality rates per million among all adults (15 to 64 years) due to drug-related deaths
DRD DRD-7. Mortality due to drug-induced deaths among all adults (15 to 64 years) in European countries for the most recent year reported Part (ii) Mortality rates among all adults (15 to 64 years) due to drug-related deaths and estimated mortality rates due to HIV/AIDS attributable to injection drug use
DRD DRD-8. Indexed long term trend in drug-induced deaths in the EU-15 Member States and Norway, 1985 to 2008
DRD DRD-9. Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2009 (three-year moving average) Part (i) Some EU Member States and Norway, 1990 to 2009
DRD DRD-9. Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2009 (three-year moving average) Part (ii) Some EU Member States, 1990 to 2009
DRD DRD-9. Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2009 (three-year moving average) Part (iii) Some EU countries, 1990 to 2009
DRD DRD-10. Mean age of drug-induced deaths in EU Member States, last year with available data
DRD DRD-11. Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole Part (i) Index in some Member States, 1985 to 2009
DRD DRD-11. Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole Part (ii) Index in some Member States, 1985 to 2009
DRD DRD-11. Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole Part (iii) Index in some Member States, 1985 to 2009
DRD DRD-12. Changes in numbers and ratio of drug-induced deaths in the EU Member States, Croatia and Norway Part (i) Changes between 2000 and 2003
DRD DRD-12. Changes in numbers and ratio of drug-induced deaths in the EU Member States, Croatia and Norway Part (ii) Changes between 2003 and 2008/9
DRD DRD-13. Number of drug-induced deaths recorded in EU Member States occurring under the age of 25 according to national definitions Part (i) EU-15 Member States and Norway 1990-2008
DRD DRD-13. Number of drug-induced deaths recorded in EU Member States occurring under the age of 25 according to national definitions Part (ii) New Member States, 1990-2008
INF INF-0. Bibliographic references
INF INF-1. Prevalence of HIV infection among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2009 or most recent year available — Summary table by country
INF INF-2. Prevalence of HCV antibody among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2009 or most recent year available — Summary table by country
INF INF-3. Prevalence of markers for HBV infection among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2009 or most recent year available — Summary table by country
INF INF-104. HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis Part (i) HIV infection in the EU countries, Croatia, Turkey and Norway: (a) cases per million population, (b) number of cases and (c) population sizes
INF INF-104. HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis Part (ii) AIDS incidence in the EU countries, Croatia, Turkey and Norway: (a) cases per million population, (b) number of cases and (c) population sizes
INF INF-105. Notified cases of hepatitis C infection among injecting drug users in the EU countries, Croatia and Norway: a) Total number of cases where transmission route known, b) number of IDU cases, and c) percentage of IDUs amongst all cases with known risk factor
INF INF-106. Notified cases of hepatitis B infection among injecting drug users in the EU countries, Croatia and Norway: a) Total number of cases where transmission route known, b) number of IDU cases, and c) percentage of IDUs amongst all cases with known risk factor
INF INF-107. Incidence studies of hepatitis C virus infection among injecting drug users in the EU countries
INF INF-108. Prevalence of HIV infection among injecting drug users (%), 1991 to 2009. EU countries, Croatia, Turkey and Norway
INF INF-109. Prevalence of HIV infection among injecting drug users under age 25 (%), 1991 to 2009. EU countries, Croatia, Turkey and Norway
INF INF-110. Prevalence of HIV infection among new (injecting less than 2 years) injecting drug users (%), 1991 to 2009. EU countries, Croatia, Turkey and Norway
INF INF-111. Prevalence of hepatitis C infection among injecting drug users (%), 1991 to 2009. EU countries, Croatia, Turkey and Norway
INF INF-112. Prevalence of hepatitis C infection among injecting drug users under age 25 (%), 1991 to 2009. EU countries, Croatia, Turkey and Norway
INF INF-113. Prevalence of hepatitis C infection among new (injecting less than 2 years) injecting drug users (%), 1991 to 2009. EU countries, Croatia, Turkey and Norway
INF INF-114. Prevalence of current hepatitis B infection among injecting drug users (% with HBsAg), 1991 to 2009. EU countries, Croatia, Turkey and Norway
INF INF-115. Prevalence of antibodies against hepatitis B virus among injecting drug users (%), 1991 to 2009. EU countries, Croatia, Turkey and Norway
INF INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2009 Part (i) Prevalence of HIV infection (percentage) among injecting drug users in Prison
INF INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2009 Part(ii) Prevalence of hepatitis C infection (%) among injecting drug users in Prison
INF INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2009 Part(iii) Prevalence of current hepatitis B infection (percentage with HBsAg) among injecting drug users in Prison
INF INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2009 Part(iv) Prevalence of antibodies against hepatitis B virus (percentage) among injecting drug users in Prison
INF INF-1. AIDS incidence by year of diagnosis among injecting drug users by country, cases per million 1998 to 2009 - EU countries, Croatia, Turkey and Norway
INF INF-2. HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 1998–2009. Part (i) EU countries, Croatia, Turkey and Norway: five highest countries in peak value 2004-2009
INF INF-2. HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 1998–2009. Part (ii) EU countries, Croatia, Turkey and Norway: countries with 5 to 10 cases per million population in peak value 2004-2009
INF INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage Part (i) All injecting drug users, 2008 to 2009
INF INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage Part (ii) Young injecting drug users (under age 25), 2008 to 2009
INF INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage Part (iii) New injecting drug users (injecting less than 2 years), 2008 to 2009
INF INF-6. HCV antibody prevalence among injecting drug users — studies with national and subnational coverage Part (i) All injecting drug users, 2008 to 2009
INF INF-6. HCV antibody prevalence among injecting drug users — studies with national and subnational coverage Part (ii) Young injecting drug users (under age 25), 2008 to 2009
INF INF-6. HCV antibody prevalence among injecting drug users — studies with national and subnational coverage Part (iii) New injecting drug users (injecting less than 2 years), 2008 to 2009
INF INF-9. Prevalence of markers of HBV infection estimated among injecting drug users — studies with national and subnational coverage Part (i) Percentage ever infected (positive for aHBc), 2008 to 2009
INF INF-9. Prevalence of markers of HBV infection among injecting drug users - studies with national and subnational coverage Part (ii) Percentage with current infection (positive for HBsAg), 2008 to 2009
EYE EYE-1. Cannabis prevalence rates Part (i) Lifetime, last year and last month prevalence of cannabis use among 15/16 year old school students (%), 2007
EYE EYE-1. Cannabis prevalence rates Part (ii) Lifetime prevalence of cannabis use among 15/16 year old school students (%), 1995, 1999, 2003 and 2007
EYE EYE-1. Cannabis prevalence rates Part (iii) Male and female lifetime prevalence of 40 or more cannabis use among 15/16 year old school students (%), 2007
EYE EYE-1. Cannabis prevalence rates Part (iv) Current (last month) prevalence of cannabis use among 15/16 and 17/18 year old school students' (%), 2003
EYE EYE-1. Cannabis prevalence rates Part (v) Lifetime prevalence of cannabis use and perceived great risk among 15/16 year old school students (%), 2007
EYE EYE-1. Cannabis prevalence rates Part (vi) Lifetime prevalence for cannabis and ecstasy use with easy availability among 15/16 school students (%), 2007
EYE EYE-2. Cannabis prevalence rates cont. Part (i) Reports of first use of cannabis aged 13 years or younger among 15/16 year old school students (%), 1999, 2003, 2007
EYE EYE-2. Cannabis prevalence rates cont. Part (ii) Lifetime prevalence of cannabis use and drinking 5 or more drinks in a row during past month among 15/16 year old school students (%), 2007
EYE EYE-2. Cannabis prevalence rates cont. Part (iii) Change in percentage lifetime prevalence of cannabis use among 15/16 year old school students, 1995-2007
EYE EYE-2. Cannabis prevalence rates cont. Part (iv) Change in percentage lifetime prevalence of cannabis use among 15/16 year old school students, 2003-2007
EYE EYE-2. Cannabis prevalence rates cont. Part (v) Trends in lifetime prevalence of cannabis use among 15- to 16-year-old school students: low prevalence countries, east and central European countries, west European countries, Slovenia and Croatia
EYE EYE-2. Cannabis prevalence rates cont. Part (vi) Comparison of trends in average (weighted) lifetime prevalence of cannabis (%) among 15-16 year old school students in Europe, USA and Australia
EYE EYE-2. Cannabis prevalence rates cont. Part (vii) Trends in average (unweighted) lifetime prevalence of cannabis (%) among 15-16 year old school students in four country groups
EYE EYE-3. Lifetime prevalence for drugs other than cannabis among school students Part (i) Changes in lifetime prevalence of ecstasy use among 15/16 year old school students (%), 1995-2007
EYE EYE-3. Lifetime prevalence for drugs other than cannabis among school students Part (ii) Changes in lifetime prevalence of ecstasy use among 15/16 year old school students (%), 2003–07
EYE EYE-3. Lifetime prevalence for drugs other than cannabis among school students Part (iii) Lifetime prevalence of ecstacy use and perceived great risk among 15/16 year olds school (%), 2007
EYE EYE-3. Lifetime prevalence for drugs other than cannabis among school students Part (iv) Last month prevalence of drinking 5+ alcoholic drinks in a row and perceived great risk among 15/16 year olds school (%), 2007
EYE EYE-3. Lifetime prevalence for drugs other than cannabis among school students Part (v) Lifetime prevalence for use of ecstasy, LSD and other hallucinogens and magic mushrooms among 15/16 year old students (%), 2007
EYE EYE-3. Lifetime prevalence for drugs other than cannabis among school students Part (vi) Lifetime prevalence for use of ecstasy and amphetamines among 15/16 year old students (%), 2007
EYE EYE-0. School surveys: Sources
EYE EYE-10. Recent school surveys (2005–2010): percentage lifetime prevalence of psychoactive substance use among students aged 15–16 years old
EYE EYE-11. School surveys: percentage lifetime prevalence of psychoactive substance use among students aged 15-16 years
EYE EYE-20. ESPAD 2007 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15-16 years Part (i) All students
EYE EYE-20. ESPAD 2007 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years Part (ii) Males
EYE EYE-20. ESPAD 2007 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years Part (iii) Females
EYE EYE-21. ESPAD 2007 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15-16 years Part (i) All students
EYE EYE-21. ESPAD 2007 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15-16 years Part (ii) Males
EYE EYE-21. ESPAD 2007 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15-16 years Part (iii) Females
EYE EYE-22. All ESPAD School Surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years Part (i) All students
EYE EYE-22. All ESPAD School Surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years Part (ii) Males
EYE EYE-22. All ESPAD School Surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years Part (iii) Females
EYE EYE-23. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15-16 years Part (i) All students
EYE EYE-23. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15-16 years Part (ii) Males
EYE EYE-23. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15-16 years Part (iii) Females
EYE EYE-30. Recent school surveys (2003-2010): percentage lifetime prevalence of psychoactive substance use and last month prevalence of cannabis among students aged 17-18 years old
DLO DLO-1. Indexed trends in reports for drug-related offences by broad type of offence in the EU Member States, 2004–09
DLO DLO-2. Offence types in reports for drug law offences in the EU Member States and Croatia, 2008 or 2009
DLO DLO-3. Indexed trends in reports for drug law offences by type of drug in the EU Member States, 2004–09
DLO DLO-4. Indexed trends in reports for offences related to drug use or possession for use in the EU Member States, 2004–09
DLO DLO-1. Drug law offences, 1995 to 2009 Part (i) Number of reports of offences
DLO DLO-1. Drug law offences, 1995 to 2009 Part (ii) Number of reports of persons
DLO DLO-1. Drug law offences, 1995 to 2009 Part (iii) Methodological notes
DLO DLO-2. Offence types in reports for drug law offences, 2008 or 2009 Part (i) Number and percentage of all reports for drug law offences
DLO DLO-2. Offence types in reports for drug law offences, 2008 or 2009 Part (ii) Methodological notes
DLO DLO-3. Drug types in reports for drug law offences, 2008 or 2009 Part (i) Number and percentage of all reports for drug law offences
DLO DLO-3. Drug types in reports for drug law offences, 2008 or 2009 Part (ii) Methodological notes
DLO DLO-4. Drug law offences related to drug use or possession for use, 2001 to 2009 Part (i) Number and percentage
DLO DLO-4. Drug law offences related to drug use or possession for use, 2001 to 2009 Part (ii) Methodological notes
DLO DLO-5. Drug law offences related to drug supply, 2001 to 2009 Part (i) Number and percentage
DLO DLO-5. Drug law offences related to drug supply, 2001 to 2009 Part (ii) Methodological notes
DLO DLO-6. Cannabis-related offences, 2001 to 2009 Part (i) Number and percentage of all drug law offences
DLO DLO-6. Cannabis-related offences, 2001 to 2009 Part (ii) Methodological notes
DLO DLO-7. Heroin-related offences, 2001 to 2009 Part (i) Number and percentage of all drug law offences
DLO DLO-7. Heroin-related offences, 2001 to 2009 Part (ii) Methodological notes
DLO DLO-8. Cocaine-related offences, 2001 to 2009 Part (i) Number and percentage of all drug law offences
DLO DLO-8. Cocaine-related offences, 2001 to 2009 Part (ii) Methodological notes
DLO DLO-109. Number of reports for drug law offences, 1985 to 2009 Part (i) Number of reports of offences
DLO DLO-109. Number of reports for drug law offences, 1985 to 2009 Part (ii) Number of reports of persons
DLO DLO-109. Number of reports for drug law offences, 1985 to 2009 Part (iii) Methodological notes
DUP DUP-1. Prevalence of lifetime drug use among prisoners, 2002-2009
DUP DUP-2. Prevalence of lifetime injecting drug use among prisoners, 2002-2009
DUP DUP-0. Prevalence of drug use among prisoners — Sources and bibliographic references
DUP DUP-1. Prevalence of lifetime drug use among prisoners, 2000–09
DUP DUP-2. Prevalence of lifetime injecting drug use among prisoners, 2000–09
DUP DUP-3. Prevalence of drug use within prison among prisoners, 2000–09
DUP DUP-4. Prevalence of injecting drug use within prison among prisoners, 2000–09
DUP DUP-105. Prevalence (percentage) of drug use among prisoners in EU Member States and Norway – full listing of studies
HSR HSR-1. Opioid substitution treatment clients as a percentage of the estimated number of problem opioid users, 2009 or most recent year available
HSR HSR-2. Estimated number of clients in opioid substitution treatment (OST) in EU 15–12, 1993–2009
HSR HSR-3. Syringes distributed through specialised programmes per estimated IDU in 2009 or most recent year
HSR HSR-4. Proportion of prison population receiving opioid substitution treatment (OST), 2008
HSR HSR-1. Year of introduction of methadone maintenance treatment (MMT), high-dosage buprenorphine treatment (HDBT), buprenorphine/naloxone combination, heroin-assisted treatment and slow-release morphine
HSR HSR-3. Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST) Part (i): Estimates of clients in methadone treatment or opioid substitution in EU-27, Croatia, Turkey and Norway, 1993–2009
HSR HSR-3. Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST) Part (ii) Estimates and share of clients in methadone (MMT) and high-dosage buprenorphine (HDBT) treatment in EU-27, Croatia, Turkey and Norway in 2009 or latest available year
HSR HSR-3. Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST) Part (iii) Methodological notes EU-27, Croatia, Turkey and Norway, 2003–2009
HSR HSR-6. Hepatitis B immunization in EU 27, Croatia, Turkey and Norway (2009)
HSR HSR-8. Responses to drug related deaths in Europe Part (i) Provision of selected responses to reduce drug related deaths in 26 EU countries, Norway and Turkey (expert ratings)
HSR HSR-8. Responses to drug related deaths in Europe Part (ii). Availability of information material on drug-related deaths and emergencies for specific target groups in 26 EU countries, Norway and Turkey
HSR HSR-2. Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU-27, Croatia, Turkey and Norway Part (i) Legal framework regarding the initiation of OST by substitution medication
HSR HSR-2. Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU-27, Croatia, Turkey and Norway Part (ii) Legal framework regarding the continuation of OST by substitution medication
HSR HSR-2. Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU-27, Croatia, Turkey and Norway Part (iii) Legal framework regarding the dispensing of substitution medications
HSR HSR-7. Health responses in prison Part (i) Level of provision of selected health responses to prisoners in 26 EU countries, Norway and Turkey (expert ratings)
HSR HSR-7. Health responses in prison Part (ii) Availability of specific responses to prisoners in 26 EU countries, Norway and Turkey (expert ratings)
HSR HSR-9. Opioid substitution treatment in prison in EU 27, Croatia, Turkey and Norway
SZR SZR-1. Estimated number of heroin seizures and quantities seized (kg) in the EU, Croatia, Turkey and Norway, 2001-2009
SZR SZR-1. Number of cannabis resin seizures, 1995 to 2009
SZR SZR-2. Quantities (kg) of cannabis resin seized, 1995 to 2009
SZR SZR-3. Number of herbal cannabis seizures, 1995 to 2009
SZR SZR-4. Quantities (kg) of herbal cannabis seized, 1995 to 2009
SZR SZR-5. Number of seizures of cannabis plants, 1995 to 2009
SZR SZR-7. Number of heroin seizures 1995 to 2009
SZR SZR-8. Quantities (kg) of heroin seized 1995 to 2009
SZR SZR-9. Number of cocaine seizures 1995 to 2009
SZR SZR-10. Quantities (kg) of cocaine seized 1995 to 2009
SZR SZR-11. Number of amphetamine seizures 1995 to 2009
SZR SZR-13. Number of ecstasy seizures 1995 to 2009
SZR SZR-15. Number of LSD seizures 1995 to 2009
SZR SZR-16. Quantities (units) of LSD seized 1995 to 2009
SZR SZR-17. Number of methamphetamine seizures, 2001 to 2009
SZR SZR-18. Quantities (kg) of methamphetamine seized, 2001 to 2009
PPP PPP-1. Indexed trends in EU retail prices for major drug types, adjusting for inflation, 2004–09
PPP PPP-1. Price of cannabis products at retail level, 2009 Part (i) Minimum, maximum, mean, median and modal price in euros
PPP PPP-1. Price of cannabis products at retail level, 2009 Part (ii) Sources of information
PPP PPP-2. Price of heroin at retail level, 2009 Part (i) Minimum, maximum, mean, median and modal price in euros
PPP PPP-2. Price of heroin at retail level, 2009 Part (ii) Sources of information
PPP PPP-3. Price of cocaine products at retail level, 2009 Part (i) Minimum, maximum, mean, median and modal price in euros
PPP PPP-3. Price of cocaine products at retail level, 2009 Part (ii) Sources of information
PPP PPP-4. Price of synthetic drugs at retail level, 2009 Part (i) Minimum, maximum, mean, median and modal price in euros
PPP PPP-4. Price of synthetic drugs at retail level, 2009 Part (ii) Sources of information
PPP PPP-5. Potency of cannabis products at retail level, 2009 Part (i) Minimum, maximum, mean, median and modal potency recorded, measured as percentage of THC content
PPP PPP-5. Potency of cannabis products at retail level, 2009 Part (ii) Sources of information
PPP PPP-5. Potency of cannabis products at retail level, 2009 Part (iii) Geographical coverage / Sampling frame / Type of study
PPP PPP-6. Purity of heroin at retail level, 2009 Part (i) Minimum, maximum, mean, median and modal purity recorded (percentage)
PPP PPP-6. Purity of heroin at retail level, 2009 Part (ii) Sources of information
PPP PPP-6. Purity of heroin at retail level, 2009 Part (iii) Geographical coverage / Sampling frame / Type of study / Purity determined to base~salt
PPP PPP-7. Purity of cocaine products at retail level, 2009 Part (i) Minimum, maximum, mean, median and modal purity recorded (percentage)
PPP PPP-7. Purity of cocaine products at retail level, 2009 Part (ii) Sources of information
PPP PPP-7. Purity of cocaine products at retail level, 2009 Part (iii) Geographical coverage / Sampling frame / Type of study / Purity determined to base~salt
PPP PPP-8. Purity of synthetic drugs at retail level, 2009 Part (i) Minimum, maximum, mean, median and modal purity recorded
PPP PPP-8. Purity of synthetic drugs at retail level, 2009 Part (ii) Sources of information
PPP PPP-8. Purity of synthetic drugs at retail level, 2009 Part (iii) Geographical coverage / Sampling frame / Type of study
PPP PPP-9. Composition of illicit drug tablets, 2009 Part (i) Content of synthetic scheduled illicit drugs
PPP PPP-9. Composition of illicit drug tablets, 2009 Part (ii) Sources of information
PPP PPP-9. Composition of illicit drug tablets, 2009 Part (iii) Sampling frame / Type of monitoring system
PPP PPP-9. Composition of illicit drug tablets, 2009 Part (iv) Information available on substances listed in categories 'Miscellaneous' and 'Other'
PPP PPP-10. Recent estimates of drug related public expenditure
GPS GPS-10. Frequency of use of cannabis amongst users in the last 30 days in national general population surveys Part (i) All adults (aged 15–64) - most recent data
GPS GPS-10. Frequency of use of cannabis amongst users in the last 30 days in national general population surveys Part (iv) Young adults (aged 15–34) - combined sources
PPP PPP-1. Price of cannabis products at retail level Part (iii) Geographical coverage / Methodology
PPP PPP-2. Price of heroin at retail level Part (iii) Geographical coverage / Methodology
PPP PPP-3. Price of cocaine products at retail level, 2009 Part (iii) Geographical coverage / Methodology
PPP PPP-4. Price of synthetic drugs at retail level, 2009 Part (iii) Geographical coverage / Methodology
PPP PPP-9. Composition of illicit drug tablets Part (v) Information available on adulterants, cutting agents and/or impurities
DLO DLO-5. Indexed trends in reports for offences related to drug supply in the EU Member States 2004–09
SZR SZR-0. Seizures of illicit drugs Part (i) Data source: name of institution and name of monitoring system/study
SZR SZR-0. Seizures of illicit drugs Part (ii) Methodological comments
SZR SZR-6. Quantities of cannabis plants seized, 1995 to 2009 Part (i) Number of plants, 1995 to 2009
SZR SZR-6. Quantities of cannabis plants seized, 1995 to 2009 Part (ii) Quantity (Kg) of plants, 1995 to 2009
SZR SZR-12. Quantities of amphetamine seized, 1995 to 2009 Part (i) Quantities (kg) of amphetamine, 1995 to 2009
SZR SZR-12. Quantities of amphetamine seized, 1995 to 2009 Part (ii) Quantities (tablets) of amphetamine, 1995 to 2009
SZR SZR-14. Quantities of ecstasy seized, 1995 to 2009 Part (i) Quantity (tablets) of ecstasy, 1995 to 2009
SZR SZR-14. Quantities of ecstasy seized, 1995 to 2009 Part (ii) Quantity (Kg) of ecstasy, 1995 to 2009
SZR SZR-19. Number of crack cocaine seizures, 1995-2009
SZR SZR-20. Quantities (kg) of crack cocaine seized 1995 to 2009
SZR SZR-21. Other substances seized, 2004 to 2009 Part(0) Other substances siezed not included in other SZR tables, 2004 to 2009
PPP PPP-2. Indexed trends in EU potency/purity for major drug types, adjusting for population size, 2004-2009
HSR HSR-4. Needle and syringe programmes (NSPs) Part (i) Year of introduction of needle and syringe programmes (NSPs), types of programmes available in 2009 and number of sites
HSR HSR-4. Needle and syringe programmes (NSPs) Part (ii) NSP geographical coverage, 2009

Page last updated: Friday, 29 April 2011